Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Can-Fite BioPharma (CANF) shares

Learn how to easily invest in Can-Fite BioPharma shares.

Can-Fite BioPharma is a biotechnology business based in the US. Can-Fite BioPharma stocks (CANF.US) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $2.32 – a decrease of 1.53% over the previous week. Can-Fite BioPharma employs 8 staff and has a trailing 12-month revenue of around $799,000.

How to buy shares in Can-Fite BioPharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CANF – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Can-Fite BioPharma stock price (NYSE MKT:CANF)

Use our graph to track the performance of CANF stocks over time.

Can-Fite BioPharma shares at a glance

Information last updated 2022-01-17.
Latest market close$1.29
52-week range$0.94 - $3.07
50-day moving average $1.29
200-day moving average $1.82
Wall St. target price$6.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.69

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Can-Fite BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Can-Fite BioPharma price performance over time

Historical closes compared with the close of $1.29 from 2022-01-19

1 week (2022-01-14) -1.53%
1 month (2021-12-21) -11.64%
3 months (2021-10-21) -17.83%
6 months (2021-07-21) -40.83%
1 year (2021-01-21) -34.85%
2 years (2020-01-21) -53.26%
3 years (2019-01-18) 7.50%
5 years (2017-01-20) 2.06

Can-Fite BioPharma financials

Revenue TTM $799,000
Gross profit TTM $763,000
Return on assets TTM -55.28%
Return on equity TTM -128.53%
Profit margin 0%
Book value $0.48
Market capitalisation $37.2 million

TTM: trailing 12 months

Can-Fite BioPharma share dividends

We're not expecting Can-Fite BioPharma to pay a dividend over the next 12 months.

Have Can-Fite BioPharma's shares ever split?

Can-Fite BioPharma's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can-Fite BioPharma shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can-Fite BioPharma shares which in turn could have impacted Can-Fite BioPharma's share price.

Can-Fite BioPharma share price volatility

Over the last 12 months, Can-Fite BioPharma's shares have ranged in value from as little as $0.9402 up to $3.07. A popular way to gauge a stock's volatility is its "beta".

CANF.US volatility(beta: 1.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can-Fite BioPharma's is 1.6889. This would suggest that Can-Fite BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Can-Fite BioPharma overview

Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site